For people with advanced nonsquamous non-small cell lung cancer (NSCLC)
Different therapies combined for one common goal—helping you live longer
You can do more to fight advanced nonsquamous NSCLC by combining ALIMTA with other treatments—specifically an immunotherapy called KEYTRUDA and platinum chemotherapy called cisplatin or carboplatin.
A treatment option for eligible patients regardless of PD-L1 (Programmed death-ligand 1) levels*:
In 2018, a study showed that there are key survival benefits of combining ALIMTA + KEYTRUDA and platinum chemotherapy.
Select Important Safety Information
If you have had a severe allergic reaction to any medicine that contains pemetrexed, tell your doctor immediately because you should not receive ALIMTA.
Proven to help slow the spread, growth, or
worsening of tumors
In a clinical study, cancer did not progress in 40% of people in the ALIMTA + KEYTRUDA and platinum chemotherapy group compared to 19% of people receiving ALIMTA and platinum chemotherapy.
ALIMTA + KEYTRUDA and platinum chemotherapy: 8.8 months without cancer spreading or getting worse; ALIMTA and platinum chemotherapy: 4.9 months without cancer spreading or getting worse.